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Abstract: We previously showed that functional N-methyl-D-aspartate (NMDA) receptors are 
expressed by human neuroblastoma cells. In this study we demonstrate functional NMDAR1 
and NMDAR2 receptors are expressed by small-cell lung cancer (SCLC) classical cell lines 
NCI H146, NCI H345, and DMS 53, by variant cell line NCI H82, and by most SCLC tumors, 
and that these receptors are important for the growth of human SCLC tumor xenografts in mice. 
Reverse transcription-polymerase chain reaction demonstrated mRNA for both receptors, with 
sequences identical to those for human mRNAs, are expressed in all four cell lines, and these 
generated proteins of the expected sizes 120 and 170 kDa. Cell viability tests showed cell growth 
was significantly (P  0.0001) impaired by NMDAR1 antagonists MK-801 and memantine. 
Ifenprodil and Ro25-6981, NMDAR2B antagonists at the polyamine site, also significantly (P  
0.001) inhibited the growth/survival of these cells. Alternatively, the glycine-binding antago-
nist, L701, 324, increased viability to 140% and 120% in NCI H345 and NCI H82 cells after 
48 hours of incubation. Immunohistochemistry of SCLC tumors with our polyclonal antibodies 
gave specific positive staining for the NMDAR1 receptor in 8 of 10 tissues examined. Small 
amounts of these same antibodies significantly reduced the growth of NCI-H345 cells up to 
25% (P  0.001). When NCI H345 cells were grown as tumor xenografts in mice, the growth 
of these tumors was reduced by 60% (P  0.001) by treatments with MK-801 over five days. 
All of these data point to active NMDAR receptors possibly having an important influence on 
SCLC growth and survival.
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Introduction
There are about 42,000 new cases of small-cell lung cancer (SCLC) in the United 
States each year. Present treatments for patients with SCLC generally involve them 
having high-dose combination chemotherapy with or without radiation therapy.1–6 
Although there is a high initial response rate to these treatments, and long-term 
survival in up to 10% of all cases,1,6–10 average life expectancy is increased by only 
8–15 months. While about 80% of these newly diagnosed SCLC patients respond to 
chemotherapy, remission generally lasts only 3–6 months. Unfortunately, there is no 
effective therapy to treat recurrent disease because it is resistant to current treatment, 
and there is also considerable toxicity associated with current chemotherapies. SCLC 
is generally regarded a neuroendocrine tumor and a number of peptides associated 
with central neurons are expressed and release by this cancer. In this study we examine 
the presence and possible importance of NMDAR1 and NMDAR2 receptors in small-
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North et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
cell lines (NCI-H345, DMS-53, DMS-146, and NCI-H82). 
Total RNA was first extracted from cell culture using 
TRIzol reagent (Invitrogen, Carlsbad, CA, USA) following 
the manufacturer recommended protocol. The synthesis 
of the cDNA was performed utilizing an oligo(dT) primer 
and reverse transcriptase (SuperScriptIII; Invitrogen). The 
cDNA synthesis was performed following manufacturer’s 
recommendation. The RNA was first denatured at 65°C for 
5 min then put on ice for 3 min. Then the reaction mixture 
was incubated at 50°C for 45 min, and 70°C for 15 min. The 
PCR with the Platinum Taq DNA Polymerase (Invitrogen) 
was performed in a Mastercycler gradient thermocycler 
(Eppendorf, Westbury, NY, USA). The reaction mixture was 
subjected to an initial denaturation at 94°C for 3 min, fol-
lowed by 30 cycles comprising a denaturation step at 94°C 
for 45 sec, a step for annealing the primers to the template at 
56°C for 45 sec, and an extension step at 72°C for 1.0 min. 
At the completion of the cycling reaction, an additional 
extension step at 72°C for 5 min was performed. NMDAR1 
primers used in PCR analysis included forward primer 1, 
5′-ATC TAC TCG GAC AAG AGC ATC C-3′, corresponding 
to nucleotide 369 to 417 (Genbank L05666); reverse primer 
1, 5′-AGC TCT TTC GCC TCC ATC AG-3′, corresponding 
to compliment nucleotide 658 to 639; forward primer 2, 
5′-AAG TAT GCG GAT GGG GTG ACT-3′ (1002 to 1022), 
reverse primer 2, 5′-CAA AAG CCG TAG CAA CAC TGA 
-3′ (1393 to 1373). NMDAR2B primers included forward 
primer 1, 5′-TCA AGG ATG CCC ACG AGA AAG -3′,   
corresponding to nucleotide residues 358 to 378 (Genbank 
NM-000834); reverse primer 1, 5′- GTG GCT TCT TCC TTG 
TGA CAG –3 (922 to 902); forward primer 2, 5′-CCA AAG 
AGC ATC ATC ACC C -3′ ( 441 to 459); reverse primer 2, 
5′-TGT AGC CAT AGC CAG TCA G -3′ (972   to 954). These 
primers were synthesized from Integrated DNA technologies, 
Inc (Coralville, IA, USA). The PCR products were purified 
by washing once with an equal volume of chloroform and 
examined on 2% agarose gels. DNase-free RNase and RNase-
free DNase (Gibco/BRL Carlsbad, CA, USA) were employed 
in some reactions to validate that the products of PCR did 
not result from initial DNA contamination.
Cloning and sequencing
Most sequencing was performed directly on RT-PCR products 
without cloning. However, in some cases fresh PCR product 
(1 µL, 4–12 ng) was cloned into a pCRTM vector and trans-
formed in One ShotTM Competent Cells using a TA Cloning 
Kit (Invitrogen). Cloned cDNAs were prepared by employing 
a Wizard Mini-preps DNA purification system (Promega, 
N-methyl-D-aspartate (NMDA) receptors types 1 and 2 
together constitute an important calcium channel for neu-
rons. This channel is activated by the natural ligands glycine 
and glutamate (NMDAR1) and glutamate (NMDAR2). The 
proper functioning of these receptors gives rise to stimulatory 
impulses between neurons and seems to be responsible for 
long-term potentiation, an essential ingredient of short-term 
memory consolidation in hippocampal and neo-cortical 
regions of the brain.11 NMDA receptors are also known to 
activate growth promoting cascades within cells, such as the 
MAP kinase and ERK pathways, leading to proliferation of 
some non-neuronal cells.12 Alternatively, overstimulation 
of NMDA receptors can lead to cell death through influx 
of excessive calcium and apoptosis, a destructive process 
that has been proposed as a factor involved in a number of 
neurodegenerative diseases, such as Alzheimer’s disease.13,14 
Recently, the NMDAR1 receptor antagonist memantine has 
been successfully introduced for therapy in the treatment of 
Alzheimer’s disease.14,15 Memantine in particular appears 
to selectively target overstimulated open NMDA channels, 
have limited side-effects, and significantly slow loss in cogni-
tion.14–16 This same drug is also being considered for the treat-
ment of other neurodegenerative diseases, such as Parkinson’s 
disease, because of the improvements of motor behavior it 
produces in MPTP-treated mice, a laboratory model for this 
disease.17 NMDAR receptors were earlier found by us to have 
similar roles in the LA-N-2 human neuroblastoma cell line.13 
Glutamate activated a calcium channel in these cells and this 
action was enhanced by the presence of glycine. Treatment 
with excess glutamate or agonist was found to lead to cell 
death, and antagonists curtailed cell growth.13
Materials and methods
Cultured cell lines
The classical human SCLC cell lines NCI-H345, DMS-
53, NCI-H146, and the variant SCLC cell line, NCI-H82, 
were obtained from American Type Tissue Culture Collec-
tion (ATCC, Rockland, MD, USA). Cells were grown and 
  maintained in Dulbecco medium or RPMI 1640 (Mediatech, 
Inc, Herndon, VA, USA) supplemented with 10% fetal bovine 
serum (Sigma Chemical Co, St Louis, MO, USA) at cell 
densities of 105 to 5 × 105/mL in a humidified atmosphere 
of 5% CO2 at 37°C.
Reverse transcription-polymerase  
chain reaction (RT-PCR)
RT-PCR was performed to evaluate the expression of 
NMDAR1 and NMDAR2B transcript in four of the SCLC Clinical Pharmacology: Advances and Applications 2010:2 33
NMDA receptors and small-cell lung cancer Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Madison, WI), and positive clones were screened with EcoR1 
restriction endonuclease (Gibco/BRL) digestion and evaluation 
on 2% agarose gels. At least two positive clones of each PCR 
product were chosen for double-strand cDNA sequencing with 
a Taq DyeDeoxyTM Terminator Cycle Sequencing kit (Applied 
Biosystems, Foster City, CA, USA). The primers designed for 
PCR amplifications, as described above, and universal primers 
(M13 Forward, M13 Reverse and T7) were engaged as sequenc-
ing primers. The protocol for DNA sequencing was modified 
as follows: 97°C for 2 min; 25 cycles at 95°C and 30 sec; 58°C 
for 1.5 min; and 72°C for 1.5 min, with a 72°C extension for 
10 min. The products were purified (×2) by phenol/chloroform 
extraction and precipitation with 100% ethanol. Sequencing 
was performed using a Model 373 DNA Sequencer (Instrument 
865; Applied Biosystems) and sequence analysis performed 
using the BLAST network service.
Western blot analysis
Cell lysates were prepared by sonication using a RIPA Buffer 
solution (1% NP-40, 1% sodium deoxycholate, 0.1% SDS, 
150 mM NaCl, 25 mM Tris/HCl, pH 7.4) with protease inhibi-
tor (Roche, Indianapolis, IN, USA), the extract centrifuged at 
12,000 × g, and the supernatant retained. The protein content 
of these extracts was assessed by differential absorbance 
measurements at 215 nm and 225 nm. Aliquots of these 
lysates representing approximately 100 µg of protein were 
first reduced with 2-mercaptoethanol in a boiling water bath 
for 5 min, then separated by SDS-PAGE on 12% gels using 
Tris/Glycine/SDS buffer (25 mM Tris, 192 mM glycine, 
0.1% SDS, pH 8.3). These gels were subjected to a voltage 
of 50 V for 10 minutes, followed by a voltage of 75 V for 
approx 2 h at ambient temperature or a voltage of 100 V for 
1 h at 4oC. The proteins were transferred onto Immobilon-P 
polyvinylidene difluoride membrane (Millipore, Bedford, MA, 
USA) in Tris/glycine/SDS buffer with 20% methanol, using 
the MiniProtean 3 system (Bio-Rad, Hercules, CA, USA). 
The membrane was blocked by drying using a Model 583 Gel 
Dryer (Bio-Rad) and by incubation with 5% bovine serum 
albumin (BSA) or 5% nonfat milk/0.1% Tween 20, followed 
by incubation with primary antibodies. PANN1 is a rabbit 
polyclonal antiserum produced in this laboratory and directed 
against an N-terminal segment of NMDAR1 (see below). 
Antibodies from this antiserum were first isolated by affinity 
chromatography. Commercially available NMDAR1 antiserum 
was obtained from Cell Signaling Technology (Beverly, MA, 
USA), and NMDAR2 antiserum was purchased from Santa 
Cruz (NMDAe2; Santa Cruz Biochemicals, Santa Cruz, CA, 
USA). The latter antiserum recognizes all NMDAR2 subunits. 
Most Western blotting involved the NMDAR1 antibody from 
Cell Signaling Technology because this commercial product 
worked better than our PANN1 antibodies with this procedure, 
while PANN1 proved to be superior for immunohistochem-
istry. The blots were visualized using a chemiluminescence 
method that employed a horseradish peroxidase-labeled goat 
antirabbit antibody (Pierce, Rockford, IL, USA, or Cell Sig-
naling), a Lumi-Light Western Blotting Substrate (Roche) or 
SuperSignal West Pico Chemiluminescent Substrate (Pierce), 
and exposure of X-ray film. They were scanned and evaluated 
using an AlphaEaseFc Stand Alone Image Machine with PC 
software (Alpha Innotech, San Leandro, CA, USA). The 
blots were stripped and incubated with GAPDH (Chemicon 
Rosemont, IL, USA), or scanned with anti- β-actin (Sigma), 
to ensure equal protein loading.
Cell growth/viability assay
A)   Effects of antagonists: Four cultured SCLC cell lines (NCI 
H82, NCI H146, NCI H345, DMS 53) were employed. 
Cells were treated with 0.05% trypsin, washed in PBS/
glycine and plated onto 96 well plates at 104 cells/well 
in medium for 24 hours to provide time for rectifying 
possible damage to membrane proteins from the tryp-
sinization. The wells were washed and incubated with 
PBS/glycine containing albumin (1.25 mg/mL) in the 
presence of differing concentrations of NMDA receptor 
antagonists(25–800 µM), and Alamar Blue (1:10 dilution 
following manufacturer’s recommendation). These antag-
onists comprised memantine and dizocilpine maleate 
(MK-801) that noncompetitively block NMDAR1 recep-
tors, Ifenprodil and Ro 25-6981 that block NMDAR2B 
receptors at the polyamine site, and L-701,252 and L-
701,324 that block NMDAR1 receptors at the glycine site. 
Fluorescent readings were taken at periods representing 
24, 48, and 72 h of incubation with antagonist using a 
Synergy HT Multi-Detection Microplate Reader and 
excitation/emission wavelengths of 530 nm and 590 nm. 
Cell viability was evaluated as % vehicle control at the 
  corresponding incubation time.
B) Effects of anti-NMDAR1 antibodies: Rabbit polyclonal 
anti-NMDAR1 antibodies (PANN1) were generated by 
us against an N-terminal extracellular peptide domain 
(-Met-Ser-Ile-Tyr-Ser-Asp-Lys-Ser-Ile-His-) of the human 
receptor, in the form of the peptide amide coupled through 
glutaraldehyde to bovine thyroglobulin as antigen, and 
use of Fruend’s complete and incomplete adjuvant.18,19 
This peptide domain is represented in that portion of the 
mRNA message sequenced by RT-PCR (see above). For Clinical Pharmacology: Advances and Applications 2010:2 34
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studies on cell proliferation, the IgGs of this antiserum 
were first isolated by precipitation with 50% saturated 
ammonium sulfate, and antibodies were then purified from 
these immunoglobulins by affinity chromatography using 
a column comprising the peptide component of the above 
antigen coupled to Sepharose.20,21 Two dilutions (1/10 and 
1/50) of an affinity purified PANN1 antibody preparation 
in PBS/0.5% BSA (375 fmol Ab and 75 fmol Ab) 
were incubated with cells in 1640 medium for 24 h at 37°C, 
and cell growth compared with cells treated liquid vehicle 
using the Alamar Blue procedure described above.
Immunohistochemistry of human  
tumor tissue
Immunohistochemical (IHC) staining for human NMDAR1 
was performed on formalin-fixed preparations from ten 
SCLC tumors representing primary, metastatic, and recurrent 
disease. These preparations were obtained from an archival 
tissue library of SCLC at the Department of Pathology, 
  Dartmouth-Hitchcock Medical Center. Tissue sections (4 µm) 
of formalin-treated material were steamed in citrate to recover 
antigen and then blocked by incubating them with 10% horse 
serum. They were then incubated for two hours at ambient 
temperature with either affinity-purified PANN1 (see above) 
in PBS/5% BSA alone, PANN1 in PBS/5% BSA containing 
an excess of peptide antigen as negative control, or PBS/5% 
BSA. Following washings (x3) in PBS/BSA, tissues were 
incubated for 1 h at ambient temperature with biotinylated 
horse anti-rabbit IgG, washed (x3), then incubated for 1 h at 
ambient temperature with streptavidin coupled to peroxidase. 
Tissues were again washed (x3) and finally reacted with a 
diaminobenzidine/peroxide mixture and contrasted with 
hemotoxylin. No effort was made in this study to detect 
NMDAR2 receptor subunits in SCLC or normal lung by 
immunohistochemistry.
Treatment of SCLC tumor  
xenografts in mice
Human tumor xenografts of SCLC cell line NCI H345 were 
raised in nu/nu mice by injecting ∼2 × 10-7 cells subcutane-
ously along the flank in 200 µl complete medium. When 
tumors of 0.5 cm diameter became established, the influ-
ence of the NMDAR1 receptor antagonist dizocilpine maleate 
(MK-801) was then examined on tumor growth measured 
daily by multiplying depth, width, and length determined 
using a micrometer. Tumor growth in a control group of ani-
mals receiving i.p. PBS vehicle (n   =   4) was compared with 
tumor growth in animals (n = 4) receiving i.p. dizocilpine 
maleate (MK-801) over 10 days. Animals received an 
escalating single dose of this NMDAR1 antagonist from 
0.1 mg/kg body weight each day for days 0–2, then to a single 
dose of 0.2 mg/kg body weight each day for days 3–6, then to 
a single dose of 0.3 mg/kg body weight each day for days 7–8. 
Finally two daily doses of 0.3 mg/kg body weight were given 
for days 8–10. This escalating dose range was designed to 
produce maximal effects without causing adverse behavioral 
changes as based on the work of others.22,23
Statistical evaluations
Results were analyzed by Analysis of Variance (ANOVA) and 
the Student–Neuman–Kuels test. Longitudinal growth data 
was evaluated using repeated measures ANOVA. Significance 
was determined to be present for P  0.05.
Results
Expression of NMDA receptors by SCLC 
cultured cells and tumor tissues
RT-PCR of poly(A+)RNA preparations from all four SCLC 
cell lines using selected forward and reverse primers, gave, 
in each case, a single overlapping product of size predicted 
from the structure of cDNA for human NMDAR1 from 
brain tissue, and reported earlier by us for human LA-N-2 
  neuroblastoma cells.13 Cloning and nucleotide sequence 
analysis of these NMDA glutamate receptor RT-PCR 
products (488 bp and 263 bp), coding for portions of the 
extracellular domain, showed them to have exact sequence 
homology with position 208–695 of the brain and neuroblas-
toma receptor, and sequence identity in this portion of the 
NMDAR1 receptor for all four SCLC cell lines. The region 
in the mRNA examined represents approximately 30% of the 
open reading frame for the extracellular N-terminal domain 
for this receptor subunit. As was found for the mRNA from 
LA-N-2 cells, there was no evidence for alternate splicing 
of the message as has been reported by Moriyoshi et al24 for 
NMDAR1 from rat brain. RT-PCR of poly(A+) RNA was 
unaffected by prior treatment of preparations with DNase, 
and no products were generated when initial treatment with 
RNase was performed or when reverse transcriptase was 
omitted from reaction mixtures. Nucleotide sequencing 
also revealed normal sequences for the two other regions of 
NMDAR1 mRNA amplified giving predicted RT-PCR prod-
ucts of 300 and 391 base pairs (Figure 1a). In addition, RT-
PCR of NMDAR2B message provided predicted products 
of 471 and 564 base pairs (Figure 1b), that upon nucleotide 
sequencing were shown to have sequences identical to those 
reported by Hess and coworkers.20 There is now a consensus Clinical Pharmacology: Advances and Applications 2010:2 35
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ies and affinity-purified PANN1 antibodies. A second minor 
band of approximately 55 kDa was also always apparent. This 
second band could be an N-terminal break-down product 
of the receptor, because both the commercial antibodies 
from Cell Signaling and PANN1 are directed against an 
N-terminal moiety of the protein (Figure 2). Alternatively, 
the NMDAR2 subunits are 165–180 kDa, and a major band of 
approximately 170 kDa (in addition to bands corresponding 
to smaller proteins) was displayed in Westerns of all SCLC 
cell lines by the Santa Cruz NMDAR2e polyclonal antibody 
(data not shown), indicating that NMDAR2A, B, or C of 
normal size is expressed by all of the cell lines. Coupled 
with RT-PCR data, we can infer that SCLC cells express 
and translate at least the NMDAR2B form of the NMDAR2 
receptor.
Immunohistochemical evaluation of SCLC tumor 
sections with anti-NMDAR1 antibodies gave strong and 
clear positive staining (+3 and +4) for eight of ten tumors 
  (Figure 3), and weak, questionable staining (+2) in the other 
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Expression of NMDAR1 receptors in SCLC cells
Expression of NMDAR2 receptors in SCLC cells
Figure 1 Genes for both NMDAR1 and NMDAR2B receptors are expressed in 
cultured small-cell lung cancer cells. A) The expression of NMDAR1 receptors in 
the cultured cell lines by RT-PCR using primers designed to amplify different regions 
of the coding sequence (see text for details). Shown are results obtained for classical 
cell lines NCI H345, NCI H146, and DMS 53, and variant cell line NCI H82. B) The 
expression of NMDAR2B receptors by cultured cell lines by RT-PCR using primers 
designed to amplify different regions of the coding sequence for this receptor (see text 
for details). Shown are results obtained for classical cell lines NCI 146 and DMS 53, 
and variant cell line NCI H82. Sequence analysis of the products using nested primers 
indicated normal NMDAR1 and NMDAR2B messages. Products were separated on 
1.5% agarose gels, which were then stained with ethidium bromide. In each case one 
band of the expected size was obtained for the amplification product.
that the molecular weight of the NMDAR1 protein subunit 
is 116 kDa, and a major band of approximately this size 
was displayed for NCI H345, NCI H82, NCI 146, and DMS 
53 cells in Western Analysis using both commercial antibod-
120 Kd
85 Kd
60 Kd
50 Kd
40 Kd
A B
Figure 2 Western analysis of NMDA receptor proteins in A) NCI H345 and   
B) NCI H82 SCLC cells. NMDAR receptor proteins are present in SCLC cancer 
cell lysates from all four cell lines. Lysates were analyzed by SDS-PAGE using 12.5% 
gels and Western blot using our own and commercial antibody preparations rec-
ognizing NMDAR1 proteins. Shown are results obtained for NCI H345 A) and   
NCI H82 B) cells with a commercial antibody against NMDAR1 protein (Cell Signaling 
Corp). Molecular mass markers (kDa) are indicated on the right side of the figure 
and demonstrate the presence in lysates of a major form protein of 116 kDa and a 
minor form of 55 kDa.
A B
Figure 3 IHC analysis of SCLC tumor: A) Positive staining with polyclonal antibody and B) Negative control with polyclonal antibody + blocking peptides. NMDAR1 protein 
is present in small-cell lung tumors. A) Positive ABC immunohistochemical staining in a tissue section of a primary tumor located in the lung of a patient using our polyclonal 
  antibodies that recognize an N-terminal peptide fragment of the receptor. Staining was concentrated at the surface of cancer cells and absent from adjacent normal cells. 
B) Control ‘peptide-negative’ ABC immunohistochemical staining in an adjacent section when the polyclonal antibodies were masked by addition of excess peptide antigen   
(magnification 20x).Clinical Pharmacology: Advances and Applications 2010:2 36
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Figure 4 Effects of NMDAR1 antagonists memantine (A,B) and MK-801 (c,d) and NMDAR2B antagonist Ifenprodil (e,F) on H345 (A,c,e) and H82 cell (B,d,F) 
proliferation after 24 h (●), 48 h (■) and 72 h (∆) of treatment. NMDAR1 and NMDAR2 receptors appear to be important for proliferation of SCLC culture cell lines. 
Percentage reduction in cell viability produced in NCI H345 classical cells (A,c,e) and in NCI H82 variant cells (B,d,F) by the action of irreversible NMDAR1 recep-
tor antagonist Memantine (a,b), irreversible NMDAR1 receptor antagonist Dizocilpine Maleate (c,d), and irreversible NMDAR2B receptor antagonist Ifenprodil (e,F) 
following 24 h (●), 48 h (■) and 72 h (∆) of treatment. Cell viability was reduced to about 10% of control as assessed using Alamar Blue staining. Reductions in viability 
were all highly significant (p  0.0001) and IC50s were obtained with 80–100 µM doses of Memantine, with ∼200 µM doses of Dizocilpine Maleate, and with 150–200 µM 
doses of Ifenprodil, at 48 and 72 h of incubation.
0
0 200 400 600
0 200 400 600 0 200 400 600
800 1000 0 200 400 600 800 1000
20
40
60
80
100
120
MK801 concentration (µM)
%
 
C
o
n
t
r
o
l
0
20
40
60
80
100
120
MK801 concentration (µM)
%
 
C
o
n
t
r
o
l
C D
0.0
20.0
40.0
60.0
80.0
100.0
120.0
140.0
Ifenprodil concentration (µM)
%
 
C
o
n
t
r
o
l
0.0
20.0
40.0
60.0
80.0
100.0
120.0
140.0
160.0
Ifenprodil concentration (µM)
%
 
C
o
n
t
r
o
l
E F
two cases examined. All of the 6 cases of metastatic and 
recurrent disease were among those giving a strong positive 
reaction. Normal cells in each section did not react with the 
antibodies. No positive staining of normal lung and liver was 
apparent with PANN1 anti-NMDAR1 antibodies for the same 
conditions of IHC, except for Kufper cells in the liver and 
isolated macrophages in both tissues (data not shown).
NMDA receptor antagonists affect 
cultured SCLC viability
Significant effects (P  0.01) on cell viability by different 
antagonists (reductions to 10% control or increases to 
140% control) were found at all three incubation times 
of 24, 48, and 72 h. The changes induced following 48 h 
and 72 h of incubation were similar, and greater than Clinical Pharmacology: Advances and Applications 2010:2 37
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those found following 24 h of incubation. Effects were 
also different for the different cell lines. Memantine 
and MK-801 produced dramatic decreases (P  0.0001) 
in cell viability (Figure 4a–d). For memantine, IC50s at 
48 h were as follows for the each cell line: 80–130 µM 
for NCI-H345 and NCI-H82; 400 µM for NCI-H146, 
and; 800 µM for DMS-53. For MK-801, IC50s at 48 h 
were as follows: 300 µM for NCI-H345 and NCI-H82; 
650 µM for NCI-H146, and; 800 µM for DMS-53. 
Both Ifenprodil and Ro 25-6981 also decreased cell 
viability (Figure 4 e,f ). For Ifenprodil, IC50M at 48 h for 
the diffent cell lines were: ∼150 and ∼200 µM for NCI-
H345 and NCI-H82 cells; a reduction no greater than 
40% with NCI-H146 cells, and; even smaller decreases 
than 40% with DMS-53. The effects of the glycine 
site binders were examined only with NCI-H345 and   
NCI-H82 cells. At 48 h, L-701,324 actually produced 
an increase in cell viability to approximately 140% and 
120% of control for NCI-H345 and NCI-H82, respectively. 
While, L-701,252 also produced an increase to approxi-
mately 120% of control for NCI-H345 cells, no clear 
effects over the concentration range used were found with 
NCI H-82 cells. Differences between different cell lines 
probably reflect either, a concentration range of recep-
tor expression, or a differing dependence of the cells on 
functional NMDARs for growth. However, effects were 
greatest on the one variant cell line (and one classical 
cell line) and this variant cell line represents recurrent 
and drug-resistant disease. It is of interest that prevent-
ing glycine from binding to NMDAR1 receptors seems to 
improve cancer cell survival, although at the concentra-
tions employed, these antagonists might be functioning 
as agonists.
Anti-NMDAR1 antibodies affect SCLC 
cultured cell viability
When PANN1 (anti-NMDAR1) rabbit polyclonal antibodies 
as an affinity-purified preparation were administered 
for 24 h at 1:50 (10 ng, 75 fmol antibody) or 1:10 
(50 ng,  0.375 fmol antibody) the proliferation of small 
cell lung cancer NCI H345 cells in culture was significantly 
(P  0.001) decreased by about 6% and 25%, respectively, 
compared with controls (Table 1). These data show an impor-
tance of NMDAR1 receptors in proliferation of this SCLC 
cell line, and suggest they may be important to other cell 
lines. They demonstrate the availability of the antigenic site 
on the receptors for antibody binding and that such binding 
disrupts signaling through these channels. Additionally, they 
imply that increased doses of these or similar antibodies, 
especially directing cell cytotoxicity in vitro and in vivo, could 
kill most, or all such cancer cells. The sequence of human 
NMDAR1 protein used to generate antibodies is identical in 
the mouse NMDAR1 protein. This means the mouse would 
be a suitable model to study the effects of anti-NMDAR1s 
on tumors in vivo.
A receptor antagonist slows tumor 
development and tumor growth
The treatment of established tumor xenografts from   
H-345 cells in nu/nu mice with MK-801 for the doses used 
produced no noticeable behavioral effects in the animals 
and had no apparent effect on their well-being as exem-
plified by body weight in treated animals paralleling that 
for controls (Figure 5a). However, MK-801 in these same 
doses produced highly significant (P  0.001) reductions 
in the rate of tumor growth, to almost 60% that of controls, 
over the course of the study (Figure 5b). This effect on 
growth was evident for even the lowest dose of 0.1 mg/kg 
body weight.
discussion
The findings presented here for SCLC cell lines and tissues 
provide strong evidence that NMDA receptors are compo-
nents of most of these neuroendocrine tumors, regardless 
of whether the tumor is primary or recurrent disease, and 
regardless of it being localized or metastatic disease. All 
four of the SCLC cells in culture, including a variant cell 
line (NCI H82) that represents recurrent and drug-resistant 
disease, were shown to express mRNAs for NMDAR1 and 
NMDAR2B that appears to be the same as that found by oth-
ers in the human brain, and, in the case of NMDAR1, by us 
for a human neuroblastoma cell line.13,2 Partial sequencing of 
these messages show sequence identity with messages from 
these other sources. These mRNAs were shown by Western 
analysis to give rise to receptor proteins of approximately 
Table 1 Anti-NMDAR1 effects on growth of NCI H345   
cancer cells
Treatment (24 h) Fluorescence of alamar blue
Control, 1:50 723.5 ± 3.8
AntiNMDAR1,1:50 678.0 ± 2.8**
Control, 1:10 811.3 ± 5.5
AntiNMDAR1, 1:10 617.0 ± 2.9**
Notes: *Significant at P  0.001 compared with control.Clinical Pharmacology: Advances and Applications 2010:2 38
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120 kDa (NMDAR1) and 170 kDa (NMDAR2B), of similar 
sizes to functional brain receptors.3 However, the commercial 
anti-NMDAR2 antibodies used could not reveal which of the 
known NMDAR2 sub-types were present on these cells, so it is 
possible that they represent all or any one of these receptors.
That NMDAR1 receptor proteins of SCLC are functional 
and important to cell growth is illustrated by the effects of the 
non-reversible NMDAR1 antagonists memantine and dizocilpine 
(MK801). Both of these antagonists dramatically reduced cell 
viability of all of the SCLC cell lines examined. The amounts 
of MK-801 producing these effects are similar to amounts 
found to alter neuronal activity in culture21,25 and intracellular 
growth cascades of lung adenocarcinoma cells26 and breast 
cancer cells27 in culture. On SCLC cells, memantine seemed 
Average body weights of the control (  ) and treated (  ) animals before and after treatment. 
Inhibition of SCLC H345 tumors in control (  ) and treated (  ) animals. 
20.0
25.0
30.0
35.0
40.0
Day
A
v
e
r
a
g
e
 
B
o
d
y
 
W
e
i
g
h
t
 
(
g
)
0 5 10 15 20
0
100
200
300
400
500
600
700
800
900
Day
%
 
T
u
m
o
r
 
G
r
o
w
t
h
0 2 4 6 8 10 12
A
B
Figure 5 NMDAR1 receptors have an influence on the growth of SCLC tumor xenografts in nu/nu mice. A) Administration of MK-801 in doses up to 0.3 mg/kg twice daily 
has no impact on the health of nu/nu mice as assessed by body weight over and beyond the treatment period. B) Growth of small-cell tumors from NCI-H345 cells is signifi-
cantly (p  0.0001) reduced by treatment with escalating doses of MK-801 from 0.1 mg/kg once daily to 0.3 mg/kg given twice daily as indicated. Tumor volume measured by 
micrometer was expressed as the product of length × width × breadth and was evaluated on a daily basis.
to be approximately twice as effective as MK-801 in vitro, 
despite it having a much lower binding affinity than the latter 
antagonist. As mentioned above, it has been proposed that unlike   
MK-801, memantine appears to selectively block overstimulated 
(“pathological”) open channels and have very few side-effects 
through normally functioning channels.14,15 If verified in vivo, we 
can anticipate memantine would have a selective action on the 
NMDA receptors of SCLC tumors, particularly recurrent tumors, 
in patients. In this regard, of special interested were effects on cells 
of the NCI H82 variant cell line, which represents recurrent and 
drug-resistant disease. This cell line, together with NCI H345, 
was the most susceptible of the cell lines examined.
We consider that proof of the principle for the assertion 
that NMDAR1 receptors are important to SCLC is provided Clinical Pharmacology: Advances and Applications 2010:2 39
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by the influence of MK-801 on the growth of tumor xeno-
grafts of NCI H345 in nude mice. A substantial reduction in 
the growth rates of these tumors to approximately 50% of 
controls was found at the end of treatment, at doses of antago-
nist that had no apparent negative influence on the health of 
animals. The uppermost dose chosen is the same as that used 
by others to increase the survival time of mice implanted 
with lung adenocarcinoma cells,26 and by us to prevent breast 
cancer growth.27 It is similar to those amounts known to have 
some influence on behavior in rodents.28–30 Such an influence 
would impose a limitation in the use of small molecules such 
as MK-801 because they can readily cross the blood-brain 
barrier and perhaps disrupt neuronal activities. However, the 
absence of any adverse effects on animal behavior observed 
here suggests doses of MK-801similar to those used could 
safely aid in the treatment of brain metastases of SCLC. The 
ideal dose levels of the antagonist and duration of treatment 
to achieve maximal impact on tumor growth has yet to be 
determined, as has the influence of other NMDAR1 and 
NMDAR2 antagonists. Support for our findings is found in 
the studies of Stepulak et al26 on mouse xenografts of human 
lung adenocarcinoma and rhabdomyosarcoma. These authors 
found treatment with MK801 increased the survival time of 
mice with lung adenocarcinoma and slowed the growth of 
rhabdomyosarcoma. But, the importance of NMDAR1 recep-
tors to SCLC is further supported by the in vitro effects that 
antibodies directed against the extracellular domain have 
on the viability of NCI H345 cells, presented in the current 
study. Additionally, although preliminary, our use of the same 
antibodies in IHC demonstrates that NMDAR1 receptors 
are present on primary and recurrent human SCLC tumors 
from different anatomical locations. All of these findings 
raise the possibility of using similar antibodies as targeting 
agents in patients for directing both diagnosis and future 
treatments. That such antibody approaches to treatment would 
not adversely affect individuals is suggested by the work of 
During and coworkers31 who were able to perform safe oral 
vaccination in animals against NMDAR1 receptors.
NMDAR2 receptor proteins also are functionally impor-
tant to, at least some, SCLC as illustrated by our findings 
with antagonists to these receptors. The specific NMDAR2B 
receptor antagonist Ifenprodil that binds to the polyamine site 
of these proteins32–34 was most effective on the cell lines NCI 
H345 and NCI H82. Ifenprodil produced large reductions 
in cell growth of both cell lines that were highly significant 
(P  0.001) over a concentration range from 150–500 µM 
(Figure 4). However there were trends towards an increase in 
growth rate in the presence of the lower concentrations of 25 
and 50 µM antagonist, and no effect with 100 µM antagonist. 
Like the findings with NMDAR1 receptor antagonists, 
maximal effects were seen after 48 h of incubation. These 
data suggest that antagonists of NMDAR2B could produce 
large decreases in SCLC tumor growth rates when given in 
appropriate amounts. In this respect, the doses of Ifenprodil 
that seem to be well tolerated in animals are higher than those 
required to generate blood concentrations compatible with 
those found here to inhibit most tumor cell growth in vitro.35 
The broader range NMDAR2 receptor antagonist Ro28-6981, 
that like Ifenprodil binds to the polyamine site, had similar 
effects on NCI H345, NCI H82, and NCI H146 cells, although 
no effects were seen on the viability of the DMS 53 cell 
line. Differences could reflect on the relative amounts and 
importance of NMDAR 2 sub-types to individual cell lines, 
and by extrapolation, to individual tumors.
Additional support for NMDAR receptors affecting tumor 
growth was the observed influence of the two ‘glycine’ site 
antagonists used here to impart significant increases in viability 
to NCI H345 and NCI H82 cells, but not produce measurable 
effects for the concentrations used on the viability of other cell 
lines examined. This somewhat puzzling outcome is thought 
to reflect an agonistic, rather than antagonistic, action of these 
substances for the concentration range employed in the study.
Our findings demonstrate that NMDA receptors are 
present on SCLC and are likely agents for maintaining cell 
growth and viability. This occurrence of these receptors on 
most SCLC has yet to be substantiated by examining a much 
larger number of cases. Additionally, the specificity of some 
of the effects recorded here will need to be established by 
observing their absence in either, as yet to be identified non-
NMDAR- expressing SCLC cells, or cells in which the expres-
sion of NMDAR receptors has been ‘knocked out’. However, 
findings already presented here raise the possibility of exploring 
new approaches for the treatment and diagnosis of most patients 
with SCLC tumors, particularly those with recurrent disease, 
that involve manipulation or blockade of these receptors.
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